Videos

Jeffrey Cohen, MD, director, Mellen Center for MS Treatment and Research, Cleveland Clinic; and president, ACTRIMS, discussed what he is looking forward to at the 2022 ACTRIMS Forum, as well as the overarching themes of the meeting. [WATCH TIME: 2 minutes]

The chief medical officer at Atara Biotherapeutics discussed the investigational agent ATA188, its mechanism to treat multiple sclerosis, and what to look for in its upcoming EMBOLD trial data readout. [WATCH TIME: 4 minutes]

The director of Cleveland Clinic’s Epilepsy Center provided insight on a new 20-year initiative to uncover more about the origins of neurological diseases and how they occur prior to symptom onset. [WATCH TIME: 3 minutes]

The chief medical officer of Prime PD spoke on motivations behind the development of the program and the unique benefits it offers amidst the ongoing COVID-19 pandemic. [WATCH TIME: 3 minutes]

The chief medical officer at Atara Biotherapeutics detailed the clinical significance of a recently published paper in Nature that adds to the evidence that Epstein-Barr virus is the leading cause of multiple sclerosis. [WATCH TIME: 3 minutes]

Discussing data from an early safety study, the chief scientific officer of FibroBiologics commented on the benefits of a staggered approach to their clinical research in multiple sclerosis. [WATCH TIME: 5 minutes]

The chief scientific officer of FibroBiologics discussed the benefits of fibroblast cell technology for this patient population, particularly the absence of adverse effects. [WATCH TIME: 3 minutes]

Alireza Atri, MD, PhD, concludes with a discussion on how different testing methods impact the care of patients with AD.

Dr Atri continues his discussion on aducanumab and AD diagnostic evaluations.

Dr Atri explains how aducanumab plays a role in diagnostic evaluations for patients with AD.

The cognitive neurologist at the University of California San Francisco discussed the need to continue research on why patients develop cognitive changes following COVID-19 infection and how clinicians can care for them. [WATCH TIME: 4 minutes]

A brief review of the unmet needs in insomnia management, particularly access to treatment and daytime functioning.

The chief scientific officer of FibroBiologics spoke on fibroblast cell technology and its specific benefits in comparison stem cell therapy. [WATCH TIME: 4 minutes]

Practical considerations for selecting a particular agent or class when treating a patient with insomnia.

The senior director of patient management, care, and rehabilitation at the National Multiple Sclerosis Society discussed the steps needed to take to improve relatively new wellness strategies. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending February 5, 2022. [WATCH TIME: 4 minutes]

The assistant clinical professor at Vanderbilt University School of Medicine discussed ways of incorporating and encouraging women physicians to enter the neurology specialty. [WATCH TIME: 4 minutes]

In light of National Women Physicians Day, the assistant clinical professor at Vanderbilt University School of Medicine commented on the roles women have played historically, and her perspective on where they stand now. [WATCH TIME: 12 minutes]

The assistant clinical professor at Vanderbilt University School of Medicine shared what National Women Physicians Day means to her, and the history behind its celebration. [WATCH TIME: 6 minutes]

The senior director of patient management, care, and rehabilitation at the National Multiple Sclerosis Society discussed the importance and flexibility of wellness approaches for patients with MS during the pandemic. [WATCH TIME: 4 minutes]

Episode 18 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the VHA; and John Greenfield, MD, PhD, of University of Connecticut School of Medicine. [WATCH TIME: 7 minutes]

The senior director of patient management, care, and rehabilitation at the National Multiple Sclerosis Society provided insight on the variability in wellness recommendations to treat symptoms of multiple sclerosis. [WATCH TIME: 6 minutes]

The founding executive director of the Alzheimer’s Drug Discovery Foundation commented on ongoing developments from the organization, particularly the diagnostics accelerator, which aims at identifying a better way to diagnose Alzheimer disease. [WATCH TIME: 6 minutes]

Alireza Atri, MD, PhD, discusses aducanumab’s recent FDA approval for the treatment of AD.

An expert explains the role biomarker testing plays when diagnosing a patient with AD.

The cognitive neurologist at the University of California, San Francisco discussed a specific analysis that evaluated differences in cerebrospinal fluid in patients who develop cognitive changes following COVID-19 infection. [WATCH TIME: 6 minutes]

Shared insight on the pharmacologic treatment landscape of insomnia, with a focus on mainstay drug classes.

Focusing on the pharmacologic setting of insomnia, experts consider when it is best to initiate therapy.

Discussing recent technological advancements in the AD field, the founding executive director of the Alzheimer’s Drug Discovery Foundation noted the doors that these innovations have opened. [WATCH TIME: 4 minutes]

The founding executive director of the Alzheimer’s Drug Discovery Foundation commented on the potential to detect patients at-risk for Alzheimer disease at an earlier age. [WATCH TIME: 4 minutes]